CCR4-NOT transcription complex subunit 1 (CNOT1)

Homo sapiens — UniProt A5YKK6

Gene: CNOT1Homo sapiensSwissProt reviewed

Data last refreshed: 2026-04-18 (UniProt release unknown)

Key facts

CCR4-NOT transcription complex subunit 1 (CNOT1) is a protein from Homo sapiens identified by UniProt accession A5YKK6, 2376 residues long. MolForge cross-references it against 0 known binders and 95 disease associations.

UniProt accession: A5YKK6; gene symbol CNOT1.
Organism: Homo sapiens.
Length: 2376 amino acids.
Top disease associations (Open Targets): holoprosencephaly 12 with or without pancreatic agenesis, Vissers-Bodmer syndrome and neurodegenerative disease.
3D structure: AlphaFold model available.

Target properties

Protein name	CCR4-NOT transcription complex subunit 1
UniProt accession	A5YKK6
Gene	CNOT1
Organism	Homo sapiens
Length	2376 residues
Molecular weight	—
EC numbers	—
Target class	—
Subcellular location	—
Keywords	—

Druggability

Target tractability assessment (Open Targets + pocket analysis). No approved drug

Druggability tier	MEDIUM
Druggability score	—
Pocket score	—
Max clinical phase	—

Disease associations (95)

Diseases linked to this target (Open Targets).

holoprosencephaly 12 with or without pancreatic agenesis · score 0.75
Vissers-Bodmer syndrome · score 0.70
neurodegenerative disease · score 0.47
Neurodevelopmental delay · score 0.46
genetic disorder · score 0.41
Neurodevelopmental disorder · score 0.40
Global developmental delay · score 0.37
complex neurodevelopmental disorder · score 0.37
pulse pressure measurement · score 0.29
Intellectual disability · score 0.27

3D Structure (1)

Experimental (PDB) and predicted (AlphaFold) structures for this protein.

Structure	Source	Method	Mean pLDDT	Resolution (Å)
AF-A5YKK6-F1	alphafold	PREDICTED	74.11	—

Experimental structures are not indexed in MolForge yet — search RCSB PDB for A5YKK6.

Amino-acid sequence (2376 residues)

MNLDSLSLAL SQISYLVDNL TKKNYRASQQ EIQHIVNRHG PEADRHLLRC LFSHVDFSGD GKSSGKDFHQ TQFLIQECAL LITKPNFIST LSYAIDNPLH YQKSLKPAPH LFAQLSKVLK LSKVQEVIFG LALLNSSSSD LRGFAAQFIK QKLPDLLRSY IDADVSGNQE GGFQDIAIEV LHLLLSHLLF GQKGAFGVGQ EQIDAFLKTL RRDFPQERCP VVLAPLLYPE KRDILMDRIL PDSGGVAKTM MESSLADFMQ EVGYGFCASI EECRNIIVQF GVREVTAAQV ARVLGMMART HSGLTDGIPL QSISAPGSGI WSDGKDKSDG AQAHTWNVEV LIDVLKELNP SLNFKEVTYE LDHPGFQIRD SKGLHNVVYG IQRGLGMEVF PVDLIYRPWK HAEGQLSFIQ HSLINPEIFC FADYPCHTVA TDILKAPPED DNREIATWKS LDLIESLLRL AEVGQYEQVK QLFSFPIKHC PDMLVLALLQ INTSWHTLRH ELISTLMPIF LGNHPNSAII LHYAWHGQGQ SPSIRQLIMH AMAEWYMRGE QYDQAKLSRI LDVAQDLKAL SMLLNGTPFA FVIDLAALAS RREYLKLDKW LTDKIREHGE PFIQACMTFL KRRCPSILGG LAPEKDQPKS AQLPPETLAT MLACLQACAG SVSQELSETI LTMVANCSNV MNKARQPPPG VMPKGRPPSA SSLDAISPVQ IDPLAGMTSL SIGGSAAPHT QSMQGFPPNL GSAFSTPQSP AKAFPPLSTP NQTTAFSGIG GLSSQLPVGG LGTGSLTGIG TGALGLPAVN NDPFVQRKLG TSGLNQPTFQ QSKMKPSDLS QVWPEANQHF SKEIDDEANS YFQRIYNHPP HPTMSVDEVL EMLQRFKDST IKREREVFNC MLRNLFEEYR FFPQYPDKEL HITACLFGGI IEKGLVTYMA LGLALRYVLE ALRKPFGSKM YYFGIAALDR FKNRLKDYPQ YCQHLASISH FMQFPHHLQE YIEYGQQSRD PPVKMQGSIT TPGSIALAQA QAQAQVPAKA PLAGQVSTMV TTSTTTTVAK TVTVTRPTGV SFKKDVPPSI NTTNIDTLLV ATDQTERIVE PPENIQEKIA FIFNNLSQSN MTQKVEELKE TVKEEFMPWV SQYLVMKRVS IEPNFHSLYS NFLDTLKNPE FNKMVLNETY RNIKVLLTSD KAAANFSDRS LLKNLGHWLG MITLAKNKPI LHTDLDVKSL LLEAYVKGQQ ELLYVVPFVA KVLESSIRSV VFRPPNPWTM AIMNVLAELH QEHDLKLNLK FEIEVLCKNL ALDINELKPG NLLKDKDRLK NLDEQLSAPK KDVKQPEELP PITTTTTSTT PATNTTCTAT VPPQPQYSYH DINVYSLAGL APHITLNPTI PLFQAHPQLK QCVRQAIERA VQELVHPVVD RSIKIAMTTC EQIVRKDFAL DSEESRMRIA AHHMMRNLTA GMAMITCREP LLMSISTNLK NSFASALRTA SPQQREMMDQ AAAQLAQDNC ELACCFIQKT AVEKAGPEMD KRLATEFELR KHARQEGRRY CDPVVLTYQA ERMPEQIRLK VGGVDPKQLA VYEEFARNVP GFLPTNDLSQ PTGFLAQPMK QAWATDDVAQ IYDKCITELE QHLHAIPPTL AMNPQAQALR SLLEVVVLSR NSRDAIAALG LLQKAVEGLL DATSGADADL LLRYRECHLL VLKALQDGRA YGSPWCNKQI TRCLIECRDE YKYNVEAVEL LIRNHLVNMQ QYDLHLAQSM ENGLNYMAVA FAMQLVKILL VDERSVAHVT EADLFHTIET LMRINAHSRG NAPEGLPQLM EVVRSNYEAM IDRAHGGPNF MMHSGISQAS EYDDPPGLRE KAEYLLREWV NLYHSAAAGR DSTKAFSAFV GQMHQQGILK TDDLITRFFR LCTEMCVEIS YRAQAEQQHN PAANPTMIRA KCYHNLDAFV RLIALLVKHS GEATNTVTKI NLLNKVLGIV VGVLLQDHDV RQSEFQQLPY HRIFIMLLLE LNAPEHVLET INFQTLTAFC NTFHILRPTK APGFVYAWLE LISHRIFIAR MLAHTPQQKG WPMYAQLLID LFKYLAPFLR NVELTKPMQI LYKGTLRVLL VLLHDFPEFL CDYHYGFCDV IPPNCIQLRN LILSAFPRNM RLPDPFTPNL KVDMLSEINI APRILTNFTG VMPPQFKKDL DSYLKTRSPV TFLSDLRSNL QVSNEPGNRY NLQLINALVL YVGTQAIAHI HNKGSTPSMS TITHSAHMDI FQNLAVDLDT EGRYLFLNAI ANQLRYPNSH THYFSCTMLY LFAEANTEAI QEQITRVLLE RLIVNRPHPW GLLITFIELI KNPAFKFWNH EFVHCAPEIE KLFQSVAQCC MGQKQAQQVM EGTGAS

External references

UniProt AlphaFold QuickGO RCSB PDB GeneCards

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

Which diseases are associated with CNOT1?

The strongest Open Targets associations for CNOT1 are holoprosencephaly 12 with or without pancreatic agenesis, Vissers-Bodmer syndrome, neurodegenerative disease, Neurodevelopmental delay and genetic disorder.

How long is the CNOT1 protein?

The Homo sapiens CNOT1 protein (UniProt A5YKK6) is 2376 amino acids long.

Browse: Targets: C · all protein targets A–Z · drugs A–Z.

Sources

UniProtKB A5YKK6 — name, gene, function, sequence, keywords (CC BY 4.0)
AlphaFold DB A5YKK6 — predicted 3D structure (CC BY 4.0)
Open Targets Platform — disease associations and tractability (CC0)

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.